Navigation Links
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
Date:8/6/2009

compounds.
  • On April 21, InterMune reported that the INFORM-1 study had been expanded by three additional cohorts to explore the interferon-free regimen in treatment-experienced patients, both treatment failures and null-responder HCV patients, and would include twice-daily dosing of ITMN-191 and significantly higher total daily doses (600mg and 900mg twice daily) than those explored in the first four patient cohorts.
  • Today the company announced that results of all seven cohorts of INFORM-1 will be presented in Presidential Plenary Session III (#193) at the 2009 AASLD meeting at 8:00 a.m. on November 3. The company also announced today that two additional abstracts on the topics of the PK/PD profile (#1594) and the viral resistance profile (#1585) of the INFORM-1 regimen have been accepted for poster presentations at the 2009 AASLD meeting, also on November 3.
  • 2009 Key Project Guidance

    The company provided the following guidance on its key development projects, pirfenidone and ITMN-191.

        Milestones And Key Events                              Expected Date
        -------------------------                              -------------
        Pirfenidone
        -----------
        Oral presentation on pirfenidone at ERS              September 14, 2009
        ---------------------------------------              ------------------
        Submission of pirfenidone NDA to FDA                            Q4 2009
        ------------------------------------                            -------
        Submission of pirfenidone MAA to EMEA                           Q1 2010
        -------------------------------------                           -------
    
        ITMN-191 (R7227)
        ---------------
        Phase 2b initiation by Roche ($20 million payment
         to InterMune)                                              August 2009
        -------------------------------------------------       
    '/>"/>
    SOURCE InterMune, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

    Related biology technology :

    1. InterMune to Release Second Quarter Financial Results on August 6
    2. InterMune to Present at Goldman Sachs Healthcare Conference
    3. InterMune Reports First Quarter 2009 Financial Results and Business Highlights
    4. InterMune to Release First Quarter Financial Results on April 30
    5. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
    6. InterMune to Present at Canaccord Adams Hepatitis C Conference
    7. InterMune to Present at Citis 4th Annual Biotech Day
    8. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
    9. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
    10. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
    11. InterMune Announces Issuance of U.S. Patent for ITMN-191
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/3/2015)... June 03, 2015 GEA's Panther™ ... which is a standalone, fully-equipped laboratory unit that is ... limited productions in pilot plants. The Panther™ NS3006L achieves ... compact design allows for easy installation with simple operation, ... This homogenizer can be used in many different industries, ...
    (Date:6/3/2015)... 03, 2015 From smart street lighting ... part in enabling success in dealing with important Societal ... leaders helped bring focus to the role and further ... Photonics21 annual meeting last week in Brussels. ... held 28 and 29 May at the Hotel Le ...
    (Date:6/2/2015)... - Shell today celebrated the North American launch of an ... exhibit the size of a city block in New ... and the public, and special appearances by industry leaders ... the best total engine protection by addressing three prominent ... corrosion. "With the launch of Shell V-Power ...
    (Date:6/2/2015)... Global Stem Cells Group subsidiary Adimarket has been named ... the regeneration and repair of human organs and tissues. The ... expansion plans in Latin America, a commitment made to meet ... stem cell therapies. , Bioquark Inc. is ... to alter the regulatory state of human tissues and organs, ...
    Breaking Biology Technology:GEA Announces the Panther™ NS3006L, a Self-Contained, Fully-Equipped Laboratory Homogenizer Well Suited for Pilot Plants 2Photonics21 Annual Meeting Focuses on Solutions for ‘Societal Challenges’ 2Photonics21 Annual Meeting Focuses on Solutions for ‘Societal Challenges’ 3New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 2New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 3New Shell V-Power NiTRO+ Premium Gasoline Introduces Breakthrough Formulation for BEST TOTAL Engine Protection 4Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 2Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 3
    ... technologies may lead to superlenses and other designer optical ... Laboratory physicist. In an article titled "Improving Metamaterials" ... issue of the journal Science , Costas Soukoulis ... to deliver certain properties not found in nature. ...
    ... TriLink BioTechnologies (TriLink), a leading provider of custom nucleic ... Hot Start solution for the PCR amplification of problematic ... When DNA targets high in GC-content are amplified, PCR ... separation and the propensity for complex secondary structure formation. ...
    ... 15, 2010 Sequenom, Inc. (Nasdaq: ... manuscript describing results from the R&D "locked-assay" verification ... Center for Molecular Medicine. (Logo: ... study entitled "Noninvasive Detection of Fetal Trisomy 21 ...
    Cached Biology Technology:Iowa State, Ames Lab physicist developing, improving designer optical materials 2TriLink BioTechnologies Launches CleanAmp™ 7-deaza-dGTP for GC-rich Target Amplification 2Sequenom Announces Publication Acceptance of Manuscript From Trisomy 21 R&D Verification Study 2Sequenom Announces Publication Acceptance of Manuscript From Trisomy 21 R&D Verification Study 3
    (Date:5/25/2015)... , May 25, 2015  Australia,s market for ... stage, although 2014 saw the advent of several trials ... 24 April 2015 is expected to ignite interest in ... in Australia . This in turn ... industry and drive new partnerships amongst vendors and distributors. ...
    (Date:5/20/2015)... , May 20, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the addition ... the Global Iris Recognition Market"  report ... , ,This research service analyses trends ... the government and commercial sectors, globally. ...
    (Date:5/18/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
    Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
    ... Sequella, Inc., a clinical-stage biopharmaceutical company focused on ... announced today that the U.S. Food and Drug ... independently reviewed Sequella lead drug compound, SQ109, and ... the treatment of tuberculosis. SQ109 shows excellent in ...
    ... - Through an international collaboration, more than 200 ... this week on the relationship between poverty and ... of Science Editors, includes presentations on seven of ... from the National Institutes of Health on Monday, ...
    ... University of Technology has joined forces with the ... that will provide an economical, green fuel alternative ... announced the multi-million dollar deal between QUT, qutbluebox, ... Government, that will see the establishment of the ...
    Cached Biology News:Sequella receives US and EU orphan drug status for SQ109 for the treatment of TB 2Sequella receives US and EU orphan drug status for SQ109 for the treatment of TB 3200 journals join in theme issues on poverty and human development 2200 journals join in theme issues on poverty and human development 3200 journals join in theme issues on poverty and human development 4200 journals join in theme issues on poverty and human development 5Global deal fuels QUT's world-changing research 2
    ... 50 X-Ray System from KUBTEC is a dual ... and three dimensional representation of the specimen under ... of specimen X-ray images, the micro focus source ... of detail in standard 2D images. The 50 ...
    ... BTX, the leader in electroporation products and ... innovative product line for experiment optimization and ... is a breakthrough in Molecular Delivery. The ... procedures that typically limited the number of ...
    ... PolarScreen Progesterone Receptor (PR) Competitor Assay ... screening novel progesterone receptor binding compounds ... assay utilizes a fusion of glutathione ... of human progesterone receptor [PR-LBD(GST)] and ...
    ... Molecular Imaging Systems group announces the ... Digital Imaging Systems, featuring high resolution ... fluorescence, luminescence, radiographic and chromogenic imaging ... CCD and 10x optical zoom lens ...
    Biology Products: